Articles tagged with Cancer Cells
Researchers at NIST developed a new method to accurately measure changes in living cell redox potential, which can serve as an indicator of cellular health and function. The technique uses nuclear magnetic resonance spectroscopy to detect glutathione levels and monitor intracellular redox reactions.
Innate lymphoid cells play key roles in protecting against infection or parasites, but their origin and function were unknown until now. Researchers identify ILCPs in fetal liver and adult bone marrow, paving the way for a better understanding of the immune system's first line of defense.
Researchers have developed a new live-cell printing technology called BloC-Printing that can print living cells onto any surface in a grid-like formation. The technology, which manipulates microfluidic physics to guide cells into hook-like traps, produces high survival rates of over 100% compared to traditional inkjet printing.
Researchers successfully controlled nanomotors inside live human cells, powered by ultrasonic waves and steered magnetically. The ability to manipulate cells from the inside holds promise for treating diseases such as cancer.
Researchers aim to make blood cancers more vulnerable to treatment by targeting the hiding spots where leukemia cells reside. Initial focus is on blood vessels, which provide a safe haven for these cells.
Researchers studied how a protein complex called Mre11-Rad50 reshapes itself to take on different DNA-repair tasks, revealing insights into its dynamic structure and biological outcomes. The findings could guide the development of better cancer-fighting therapies and more effective gene therapies.
Researchers found that aggressive thyroid cancer cells in microgravity exhibit a redifferentiation to a less aggressive state, offering hope for new treatments. The study's findings suggest potential therapeutic targets for cancer drugs that may be effective on Earth.
Researchers discovered that DNA damage triggers dramatic reorganization of the Golgi, leading to its dispersal throughout the cell. This dispersal involves a novel signaling pathway directly linking DNA damage response to the Golgi, affecting cell survival and chemotherapy efficacy.
A study by Virginia Tech researchers reveals that brain tumor cells with diverse physical traits are safer due to chromosomal abnormalities. These abnormalities lead to cell diversity and survival of brain tumors.
Researchers discovered a targeted treatment's mechanism of action, which involves the PML/p53 pathway and senescence. The treatment's effectiveness relies on reorganizing nuclear bodies and triggering p53 activation, leading to the elimination of cancer cells and patient recovery.
Researchers from University of Copenhagen develop method for slow release drugs by attaching liquid crystalline particles to cancer cells. The particles can carry large quantities of drugs and interact with cellular membranes, providing a potential solution to frequent injections and side effects.
Researchers at the University of Edinburgh have discovered a set of proteins that stabilise cell division, which could lead to new avenues in drug discovery for fighting cancer. The findings shed light on how cells duplicate their DNA and separate into two new cells, each identical to the original.
A new study suggests that autophagy plays a key role in determining the fate of cancer cells when treated with anti-cancer drugs. Cells with high levels of autophagy were more susceptible to death from certain drugs, while those with low levels of autophagy were more resistant.
The study reveals that E6AP is composed of three distinct protein molecules, controlling nerve cell function and viral replication. This breakthrough provides potential drug targets for autism and cervical cancer treatment.
Researchers found that activating p53 in normal cells induces Par-4 secretion, killing cancer cells. The paracrine effect targets tumor cells at distant sites, offering a new approach to treating tumors resistant to other treatments.
Researchers have discovered that a cancer drug can protect the insulin-producing cells in the pancreas and prevent the development of type 1 diabetes in mice. The medication works by reducing sterile inflammation and delaying cell destruction. This finding is a step towards developing a preventive treatment for type 1 diabetes.
Walter and Eliza Hall Institute researchers discovered that lymphoma cells with high levels of MYC are sensitive to disabling protein MCL-1, making it a potential target for treating cancers driven by this common cancer-causing change in cells.
Researchers at Cornell University have discovered a new way to destroy metastasizing cancer cells by hitching killer proteins to white blood cells. The treatment, which uses E-selectin and TRAIL proteins, was found to be nearly 100% effective in killing cancer cells in laboratory tests.
Researchers at the University of California, San Diego School of Medicine found that combining ROR1 and TCL1 oncogenes in mice accelerates and worsens blood cancer. The study suggests ROR1 could be an important therapeutic target for patients with CLL, a common form of blood cancer affecting over 15,000 new cases annually.
Scientists at the University of Exeter have identified four distinct routes for cell division, which could lead to errors in cell division and increase cancer risk. The study also found a central molecular complex, Augmin, essential for all these pathways.
Researchers at UT Southwestern Medical Center identified BRD4 as a potential therapeutic target for MPNST, a rare and aggressive type of soft-tissue cancer. Inhibiting BRD4 caused cancer cells to die in a mouse model, providing new hope for patients with this incurable disease.
Researchers develop new treatment for pancreatic cancer by using a drug that breaks down the protective barrier surrounding cancer tumours. The approach enables T cells to get through and kill cancer cells, resulting in almost complete elimination of cancer cells in initial tests.
A study in the Journal of Dairy Science found that polyphenol EGCG in milk can reduce colon cancer cell proliferation and inhibit tumor formation. Milk's casein protein micelles may enhance bioavailability and efficacy of these compounds.
Research reveals that fusion between cancer cells and macrophages empowers cancer cells to spread, forming tumors more rapidly. The study's findings suggest a new mechanism by which cancer progression is driven.
Researchers identify two therapeutic targets to block cancer cell growth: PAK and STAT5. The shutdown of either target significantly delays leukemia progression in mice, offering new hope for cancer treatment.
A research group at Lund University has shown that the 'avalanche effect' theory of cancer development is not correct. Cancer cells can have over 100 chromosomes, but a single initial change does not lead to unstoppable further mutations.
A toxin linked to brentuximab vedotin has shown compelling antitumor activity in patients with non-Hodgkin lymphomas, including diffuse large B cell lymphoma. The study found that 40% of DLBCL patients had an objective response, with a median duration of 36 weeks.
Scientists at VTT Technical Research Centre of Finland have discovered a novel DNA repair mechanism in cancer cells that allows them to survive DNA damage. This finding provides valuable insights into how cancer cells evade programmed cell death and can be targeted by new cancer therapies.
A new optical sensor created at MIT can track zinc within cells, shedding light on its functions and helping researchers study zinc trafficking in prostate cells. The sensor supports the theory that cancerous prostate cells banish zinc from mitochondria to produce extra energy.
A personalized cell therapy reprograms a patient's immune system to eliminate tumors in blood, showing complete responses in 89% of patients with high-risk ALL. The treatment has also been shown to persist in circulation and prevent cancer recurrence.
Researchers have discovered that tumour cells adopt the 'break-induced replication' (BIR) pathway to repair damaged replication forks, allowing for genome duplication. This pathway is common in cancer cells but rare in healthy cells, revealing a significant difference between these two types of cells.
Researchers at the University of Colorado have synthesized the most active component of grape seed extract, B2G2, which induces apoptosis in prostate cancer cells while leaving healthy cells unharmed. The findings suggest that B2G2 is a promising lead compound for future clinical trials and preclinical studies.
Researchers found that inhibiting antioxidant proteins reduced tumor growth and induced cell death in lung cancer cells. In a mouse model, the inhibitor ATN-224 also reduced tumor sizes when combined with another drug.
Researchers discovered a unique leukemia-specific DNA enhancer element that enables cancerous blood cells to proliferate in Acute Myeloid Leukemia (AML), a devastating and incurable cancer. The study also reveals how a new class of promising drugs, including JQ1, halt the growth of cancer cells by targeting this enhancer element.
Researchers have unveiled a biological process that explains how DNA can be damaged during genome replication, which relies on protein RPA. Cells use this protein as 'band aids' to protect DNA temporarily during replication, but if they run out, DNA breaks severely and cells cannot divide.
A new technique, deformability cytometry, can analyze over 1,000 cells per second and provide more accurate diagnoses than traditional methods. The test uses fluid flow to 'squeeze' individual cells, allowing for detailed analysis of cell properties.
Researchers at the University of Adelaide have discovered a gene that plays a crucial role in suppressing lymphoma, a type of blood cell cancer. Caspase-2 helps maintain healthy chromosome numbers in cells, preventing them from becoming cancerous.
Researchers used DNA sequencing to create a family tree for individual cancer cells, revealing unique branching patterns and distinct sub-populations. This technique could help identify key mutations driving tumor growth and develop targeted treatments more effectively.
Researchers have identified FOX01 as a critical molecule in the wound-healing process, providing a possible new target for pharmaceuticals. The study found that FOX01 plays an integral role in activating key growth factor TGF-β1 and protecting cells against oxidative stress.
A CNIO team has discovered that senescence, which makes cells stop dividing, also takes place during embryo development to eliminate unnecessary cells. This process, known as programmed senescence, helps shape the body's tissues and organs.
A peptide fragment derived from cow's milk, lactoferricin B25, exhibits potent anticancer capability against human stomach cancer cell cultures. This finding provides support for the potential therapeutic agent for gastric cancer treatment.
Whitehead Institute scientists report that the FLCN protein acts as a trigger to activate the mTORC1 pathway, which regulates cell growth in response to nutrient levels. This unexpected finding may provide insight into how cancer cells distort normal cellular functions to maintain their own harmful ways.
Researchers at the University of Nottingham have found a type of archaea that can reproduce without normal replication processes, growing faster in its absence. This discovery challenges existing understanding of DNA replication and has implications for cancer research.
Researchers at Boston University School of Medicine suggest epigenetics as a target for cancer therapy. Epigenetic changes mediate the development of cancer progenitor cells, which can grow rapidly to become full-fledged cancer.
The Cell-CT platform detected lung cancer in patient sputum samples with a sensitivity of over 95% and specificity of 99.8%. The technology creates comprehensive 3D digital images of cells, making it possible to determine the presence or absence of cancer with great accuracy.
Researchers discovered that individual molecular muscles within cells respond differently to various forces, shedding light on how cells 'feel' their environment. A computer model predicts cell behavior in response to altered levels of these molecules, with implications for understanding cellular disorders like cancer and neurodegenera...
Researchers at UCSF have discovered a new way to target cancer by controlling cell growth and boosting protein production during the S phase of the cell cycle. This study has implications for the development of new cancer therapies.
Researchers discovered distinct EBV subtypes with varying public health risks, including a strain associated with nasopharyngeal carcinoma. This finding highlights the importance of tailoring prevention efforts to specific viral strains.
Researchers at CNIO's Cell Division & Cancer Group have discovered that the protein Greatwall is essential for preventing mitotic collapse in mammals. By inhibiting Greatwall, cells can no longer divide properly, which may lead to slowed-down cancer growth and potentially reactivated tumour suppressor PP2A
A study finds that chronic myeloid leukemia cells with activating beta-catenin mutations are highly aggressive and resistant to Imatinib. Combined treatment with drugs restoring IRF8 expression and inactivating beta-catenin may prevent fatal leukemia progression.
A team of engineers has developed a new approach that marries computer vision and hardware optimization to sort cells up to 38 times faster than current techniques. The approach improves on imaging flow cytometry, which uses camera mounted on a microscope to capture cell features.
A study at the Weizmann Institute suggests that in a quarter of all leukemias, cancer cells use a balance between a mutated gene and its normal counterpart to keep going. The healthy RUNX1 gene plays a crucial role in blood cell development and maintenance.
A phase I clinical trial has shown that an anti-PD-L1 monoclonal antibody can produce striking responses in non-small cell lung cancer patients with metastatic disease who have failed to respond to previous chemotherapy. Smokers and former smokers are more likely to benefit from this treatment.
Researchers found that men with variable telomere length in cancer cells and shorter telomeres in stromal cells were more likely to develop metastatic disease and die sooner from their prostate cancer. This combination could be a marker for prostate cancer prognosis.
Cancer researchers at UC San Diego isolated and characterized early-stage prostate cancer cells, which may drive recurrent disease. The study suggests that these cells could be targeted for new treatments, potentially reducing cancer progression.
A team of U-M neuroscientists reports that SIRP alpha plays a critical role in stabilizing the most active synaptic connections between brain cells. This finding may aid research on conditions like autism, schizophrenia, and intellectual disability, which are linked to abnormal synapse function.
The circadian clock enables cells to use stored fuel efficiently when we fast, with NAD+ and Sirtuin 3 playing a critical role. Disrupting the clock leads to metabolic disorders, but providing NAD+ supplements can restore mitochondrial function.
A study published in the Journal of the National Cancer Institute found that proteins delivering leucine to prostate cancer cells are therapeutic targets. Inhibition of these proteins inhibits nutrient signaling pathways and over 100 metastasis-related genes, leading to cell cycle inhibition and reduced tumor growth.
Scientists at A*STAR's Singapore Immunology Network have discovered a new mechanism involving p53, the famous tumor suppressor, to fight against aggressive cancers. The strategy works by sabotaging cancer cells' ability to hide from the immune system, opening a new avenue for targeted therapy.
Scientists at the University of Copenhagen have identified a specific sugar molecule that aids in the growth of cancer cells. The discovery, published in PNAS, could lead to new ways to diagnose and treat cancer.